This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Garcia, J. A. Articles by Dreicer, R. Search for Related Content PubMed PubMed Citation Articles by Garcia, J. A. Articles by Dreicer, R. Social Bookmarking                            What's this?

Systemic Chemotherapy for Advanced Bladder Cancer: Update and Controversies

Jorge A. Garcia, Robert Dreicer

From the Departments of Solid Tumor Oncology, Glickman Urologic Institute, Cleveland Clinic Taussig Cancer Center, Cleveland, OH

Address reprint requests to Jorge A. Garcia, MD, Cleveland Clinic Taussig Cancer Center, 9500 Euclid Ave, R35, Cleveland, OH 44195; e-mail: garciaj4{at}ccf.org

Despite improvements in surgical techniques and outcomes, 5-year survival rates for patients with muscle-invasive bladder cancer remain suboptimal. Almost 50% of patients will eventually progress and develop systemic disease. Although various single agents have shown activity in patients with advanced or metastatic disease, randomized trials have demonstrated the utility of cisplatin-based combinations regimens. Despite relatively high objective response rates, the impact on survival in patients with advanced disease has been quite limited. Surgical resection in selected patients achieving significant objective response to cytotoxic therapy can contribute to long-term survival rates. The role of salvage therapy in advanced disease remains undefined. Evaluation of several active compounds has yielded unimpressive results with low objective response rates and overlapping CIs. Recognition that the maximum benefit from conventional cytotoxics has been achieved has led to the recent initiation of a number of clinical trials evaluating targeted agents in the management of advanced urothelial cancer.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				R. Dreicer Second-Line Chemotherapy for Advanced Urothelial Cancer: Because We Should or Because We Can? J. Clin. Oncol., September 20, 2009; 27(27): 4444 - 4445. [Full Text] [PDF]

				D. F. Bajorin, R. J. Motzer, and G. J. Bosl Advances in Urologic Oncology: Results Progress From Successful Interdisciplinary Research J. Clin. Oncol., December 10, 2006; 24(35): 5479 - 5481. [Full Text] [PDF]